Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages
Purpose: Monocytes serve as sanctuary sites for HIV-1 from which virus is difficult to be eliminated. Therefore, an effective viral suppression in monocytes is critical for effective antiretroviral therapy (ART). This study focuses on a new strategy using nanoformulation to optimize the efficacy of...
Main Authors: | Yuqing Gong, Pallabita Chowdhury, Narasimha M. Midde, Mohammad A. Rahman, Murali M. Yallapu, Santosh Kumar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-12-01
|
Series: | Biochemistry and Biophysics Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580817302145 |
Similar Items
-
An Elvitegravir Nanoformulation Crosses the Blood–Brain Barrier and Suppresses HIV-1 Replication in Microglia
by: Yuqing Gong, et al.
Published: (2020-05-01) -
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir
by: Andrea R. Thurman, et al.
Published: (2023-04-01) -
Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaquesResearch in context
by: Natalia Makarova, et al.
Published: (2022-12-01) -
A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients
by: Margherita Bracchi, et al.
Published: (2021-11-01) -
Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
by: Javier Perez Stachowski, et al.
Published: (2022-08-01)